ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant
Summary
The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.
What changed
The USPTO granted Patent US12600733B2 to Eli Lilly and Company covering KRAS inhibitor compounds of specified formula, their pharmaceutically acceptable salts, and methods of using these compounds for treating patients with cancer. The patent contains 30 claims and lists 11 inventors across various named compounds and pharmaceutical compositions.
For pharmaceutical companies and research organizations, this patent establishes exclusive rights for Eli Lilly in the KRAS inhibitor space for cancer treatment. Competitors developing similar compounds may need to evaluate freedom-to-operate or consider licensing arrangements. The patent's issuance reinforces Eli Lilly's position in targeted oncology therapies and may impact competitive landscape for KRAS-targeted cancer treatments.
What to do next
- Monitor for potential licensing opportunities
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KRAS inhibitors
Grant US12600733B2 Kind: B2 Apr 14, 2026
Assignee
ELI LILLY AND COMPANY
Inventors
Adedoyin David Abraham, Sean Aronow, Desta Bume, Xiaohong Chen, Sonia Maria Gutierrez Sanfeliciano, Timothy Scott Kercher, Wenceslao Lumeras Amador, Ramkumar Rajamani, Isabel Rojo Garcia, William Rush Scaggs, Shane Walls
Abstract
Provided herein are compounds of the formula: wherein A, B, R1, R2, R3a, R3b, Z1, Z2, and Z3 are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients with cancer.
CPC Classifications
C07D 519/00 C07D 491/048 A61P 35/00 A61K 31/4741 A61K 31/5025 A61K 31/519 A61K 31/5377 A61K 31/5383 A61K 45/06 C07B 59/002
Filing Date
2025-09-30
Application No.
19344841
Claims
30
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.